Gennigens C, Collignon J, Jerusalem G, et al.- Anticorps monoclonaux à usage thérapeutique en hémato-oncologie: généralités. Rev Med Liege, 2009, 64, 264-267.
Orlando L, Schiavone P, Fedele P, et al. - Molecularly targeted endocrine therapies for breast cancer. Cancer Treat Rev, 2010, 36, S67-S71.
Di Leo A, Jerusalem G, Petruzelka L, et al. - Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol, 2010, 28, 4594-4600.
Lin NU, Winer EP. - New targets for therapy in breast cancer : small molecule tyrosine kinase inhibitors. Breast Cancer Res, 2004, 6, 204-210. (Pubitemid 39220375)
Hicks DG, Kulkarni S. - Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing. Arch Pathol Lab Med, 2008, 132, 1008-1015. (Pubitemid 351918709)
Spector NL, Blackwell KL. - Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol, 2009, 27, 5838-5847.
Jahanzeb M. - Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin Breast Cancer, 2008, 8, 324-333.
Garnock-Jones KP, Keating GM, Scott LJ. - Trastuzumab: A review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. Drugs, 2010, 70, 215-239.
Petrelli F, Borgonovo K, Cabiddu M, et al. - Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer : a pooled analysis of two randomized trials. Anticancer Drugs, 2011, 22, 128-135.
Banerjee S, Smith IE. - Management of small HER2-positive breast cancers. Lancet Oncol, 2010, 11, 1193-1199.
Costa RB, Kurra G, Greenberg L, Geyer CE. - Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol, 2010, 21, 2153-2160.
Roy V, Perez EA. - Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer. Oncologist, 2009, 14, 1061-1069.
Bischoff J, Ignatov A. - The role of targeted agents in the treatment of metastatic breast cancer. Breast Care (Basel), 2010, 5, 134-141.
Abramson V, Arteaga CL. - New strategies in HER2-overexpressing breast cancer : many combinations of targeted drugs available. Clin Cancer Res, 2011, 17, 952-958.
Giampaglia M, Chiuri VE, Tinelli A, et al. - Lapatinib in breast cancer : clinical experiences and future perspectives. Cancer Treat Rev, 2010, 36, S72-S79.
Baselga J, Swain SM. - CLEOPATRA : a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. Clin Breast Cancer, 2010, 10, 489-491.
Burris HA, III, Rugo HS, Vukelja SJ, et al. - Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol, 2011, 29, 398-405.
Burstein HJ, Sun Y, Dirix LY, et al. - Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol, 2010, 28, 1301-1307.
Hernandez-Aya LF, Gonzalez-Angulo AM. - Targeting the Phosphatidyl Inositol 3-Kinase Signaling Pathway in Breast Cancer. Oncologist, 2011, Mar 15 [Epub ahead of print].
Baselga J. - Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist, 2011, 16,12-19.
Jerusalem G, Fasolo A, Dieras V, et al. - Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat, 2011, 125, 447-455.
Miller K, Wang M, Gralow J, et al.- Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med, 2007, 357, 2666-2676.
Collignon J, Struman I, Tabruyn S, et al. - Aspects moléculaires du cancer du sein triple négatif et les implications thé rapeutiques. Rev Med Liège, 2011, 66, 393-396.
Domagala P, Huzarski T, Lubinski J, et al. - PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors : possible implications for PARP-1 inhibitor therapy. Breast Cancer Res Treat, 2011, 127, 861-869.
